STOCK TITAN

Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Apyx Medical Corporation (APYX) to release financial results for Q4 and FY 2023 on March 21st, with a conference call to discuss the outcomes.
Positive
  • None.
Negative
  • None.

CLEARWATER, Fla.--(BUSINESS WIRE)-- Apyx® Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2023 will be released before the market opens on Thursday, March 21st.

Management will host a conference call at 8:00 a.m. Eastern Time on March 21st to discuss the results of the quarter and year, and to host a question and answer session. To listen to the call by phone, interested parties may dial 877-407-8289 (or 201-689-8341 for international callers) and provide access code 13744178. Participants should ask for the Apyx Medical Corporation Call. A live webcast of the call will be accessible via the Investor Relations section of the Company’s website and at:

https://event.choruscall.com/mediaframe/webcast.html?webcastid=KtFzwD3M

A telephonic replay will be available approximately three hours after the call ends through the following two weeks. The replay can be accessed by dialing 877-660-6853 for U.S. callers or 201-612-7415 for international callers and using the replay access code: 13744178. The webcast will be archived on the Investor Relations section of the Company’s website.

About Apyx Medical Corporation:

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

Investor Relations:

ICR Westwicke on behalf of Apyx Medical Corporation

Mike Piccinino, CFA

investor.relations@apyxmedical.com

Source: Apyx Medical Corporation

Apyx Medical Corporation will release financial results for the fourth quarter and fiscal year 2023 before the market opens on Thursday, March 21st.

Apyx Medical Corporation manufactures and sells a proprietary helium plasma and radiofrequency technology marketed as Renuvion®.

The conference call to discuss the results of the quarter and year will be held at 8:00 a.m. Eastern Time on March 21st.

Interested parties can listen to the call by phone by dialing 877-407-8289 (or 201-689-8341 for international callers) and providing access code 13744178.

A live webcast of the call will be accessible via the Investor Relations section of the Company’s website and at the provided webcast link.
Apyx Medical Corporation

NASDAQ:APYX

APYX Rankings

APYX Latest News

APYX Stock Data

48.50M
24.98M
17.92%
48.15%
2.04%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
CLEARWATER

About APYX

apyx medical corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. it operates in two segments, advanced energy and original equipment manufacturing (oem). the company develops j-plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. it markets and sells helium plasma technology under the renuvion brand name in the cosmetic surgery market and under the j-plasma brand name in the hospital surgical market. the company's renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the j-plasma system allows surgeons to operate in eliminating unintended tissue trauma. it also designs, develops, manufactures, and sells electrosurgical and oem generators and related accessories for medical device manufacturers. the company was formerly known as bovie medical corporation and changed